Advancing Bladder Preservation: Biomarkers, Decision-Making, and Therapy (2020)

Baltimore, MD US
March 6, 2020 to March 7, 2020

Johns Hopkins Greenberg Bladder Cancer Institute and American Urological Association Translational Research Collaboration

“Advancing Bladder Preservation: Biomarkers, Decision-Making and Therapy” is the third annual translational research collaboration co-sponsored by the Johns Hopkins University Greenberg Bladder Cancer Institute and American Urological Association. This year’s meeting will be held on March 6-7, 2020 at the Johns Hopkins East Baltimore Medical Campus in Baltimore, Maryland. The meeting will be a two-day workshop focused on alternatives to surgical removal of the bladder (radical cystectomy) for patients with muscle-invasive disease. The biological determinants of sensitivity and resistance to radiation therapy-based bladder preservation are unknown and the field lacks biomarkers that could be used for patient selection. There are candidate biomarkers for bladder preservation following treatment with neoadjuvant cisplatin-based chemotherapy, and the meeting will provide a timely opportunity to review the status of ongoing validation studies.

    Program Planning Committee

    • David McConkey, PhD (Chair) - Johns Hopkins University Greenberg Bladder Cancer Institute
    • Trinity Bivalacqua, MD, PhD - Johns Hopkins Hospital
    • Peter Black, MD - University of British Columbia
    • Jason Efstathiou, MD, PhD - Massachusetts General Hospital
    • Yair Lotan, MD - UT Southwestern
    • Arlene Siefker-Radtke, MD - MD Anderson Cancer Center
    • Phuoc Tran, MD, PhD - Johns Hopkins School of Medicine

    Course Registration Fees

    The registration deadline is February 24, 2020.

     AUA MemberNon-Member
    PhD Research Scientist$200$250
    Resident, Fellow, Trainee, or Student$150$175
    Medical Professional Employed by Industry*$450 (Please call AUA Customer Service at 1-800-908-9414 to register by phone.)

    Target Audience

    • Urologists
    • Research scientists
    • Clinical and research faculty
    • Clinical and postdoctoral fellows
    • Residents
    • Medical and graduate students
    • Medical professionals employed by industry

    *For exhibit/promotional opportunities, please contact Keith Price at or at 410-689-3749.

    Learning Objectives

    After completing this activity, participants will be able to:

    1. Describe the state of the science in bladder cancer biomarker identification and validation to assist in treatment decision-making toward bladder preservation or cystectomy.
    2. Discuss the potential role of hypoxia modulation in optimization of bladder cancer therapies that enable preservation of the bladder.
    3. Describe the relevant surgical and clinical variables associated with patient outcomes after various options for bladder cancer treatment.
    4. Explain patient perspectives on the treatment options after bladder cancer diagnosis.


    This activity is supported by independent educational grants from:

    • AstraZeneca
    • Bristol-Myers Squibb
    • Genentech
    • Merck
    • UroGen Pharma

    The AUA would also like to thank the following companies for providing exhibitor support:

    • Bristol-Myers Squibb
    • Janssen Biotech
    • Merck
    • Pfizer
    • Photocure
    Course summary
    Available credit: 
    • 9.50 AMA PRA Category 1 Credit™
    • 9.50 Non-Physician Participation
    Course opens: 
    Course expires: 
    Event starts: 
    03/06/2020 - 2:00pm EST
    Event ends: 
    03/07/2020 - 3:10pm EST

    *agenda updates will be posted as they become available

    Friday, March 6, 2020

    2:00 PMArrival, Registration, Light Refreshments
    2:30 PMWelcome, Opening Remarks, Goal Setting

    David McConkey, PhD
    Johns Hopkins Greenberg Bladder Cancer Institute


    Aria Olumi, MD
    AUA Research Chair; Beth Israel Deaconess Medical Center and Harvard Medical School


    Carolyn Best, PhD
    AUA Research Director

    2:40 PMPatient Perspectives Panel: Lived Experience with or without Bladder Preservation

    Moderator: Stephanie Chisolm, PhD
    Bladder Cancer Advocacy Network


    Panel Members:
    Joy Burt, RN
    Thomas Reed
    Robert P. Schreiber
    Frederick Starr

    3:40 PMDiscussion, Q&A 
    4:10 PMBreak 
    4:25 PMSetting the Stage: Current Criteria for Bladder Preservation, Disqualifiers, and Other Considerations

    Jason Efstathiou, MD, DPhil
    Massachusetts General Hospital

    4:50 PMSpeaker Panel: Targeting Barriers to Wider Use of Trimodal Therapy

    Seth Lerner, MD
    Baylor College of Medicine


    Leslie Ballas, MD
    University of Southern California


    Parminder Singh, MD
    Mayo Clinic College of Medicine

    5:35 PMComparison of Costs of Radical Cystectomy vs. Trimodal Therapy for Patients with Localized Muscle-Invasive Bladder Cancer

    Stephen B. Williams, MD, MS
    The University of Texas Medical Branch at Galveston

    5:50 PMKEYNOTE: Breaking Down Barriers in Knowledge Translation

    Anna R. Gagliardi, PhD
    University of Toronto

    6:20 PMDiscussion, Q&A 
    6:40 PMNetworking Reception and Dinner
    Please email with any food allergies in preparation for the event.
    8:00 PMAdjourn 

    Saturday, March 7, 2020

    7:30 AMBreakfast and Morning Registration 
    8:00 AMOpening, Recap from Previous Day, and Goal Setting

    Peter Black, MD
    University of British Columbia

    8:10 AMSession 2: Surgical Issues - Moderator's Introduction

    Seth Lerner, MD
    Baylor College of Medicine

    8:15 AMStandardizing TURBT in Bladder Preservation Therapy

    Wassim Kassouf, MD, CM
    McGill University

    8:30 AMUse of Fiducial Markers

    Girish S. Kulkarni, MD, PhD
    University of Toronto

    8:45 AMNeed for Re-TURBT/Biopsy during Follow-up

    Adam S. Feldman, MD, MPH
    Massachusetts General Hospital

    9:00 AMRadical Cystectomy and Diversion Options after Failed RT to Bladder

    Trinity Bivalacqua, MD, PhD
    Johns Hopkins University

    9:15 AMBladder Preservation in Advanced Disease

    Ashish M. Kamat, MD, MBBS
    University of Texas MD Anderson Cancer Center

    9:30 AMPanel Discussion and Q&A 
    9:50 AMBreak 
    10:05 AMSession 3: Systemic Therapy Issues - Moderator's Introduction

    Andrea Apolo, MD
    National Cancer Institute

    10:10 AMChemotherapy: Neoadjuvant vs. Concomitant

    Srikala Sridhar, MD, MSc, FRCPC
    Princess Margaret Cancer Center

    Parminder Singh, MD
    Mayo Clinic College of Medicine

    10:30 AMTreatment Options for Cisplatin Ineligible Urothelial Cancer Patients

    Pooja Ghatalia, MD
    Fox Chase Cancer Center

    10:45 AMCheckpoint Blockade

    Noah Hahn, MD
    Johns Hopkins University

    11:00 AMDefinitive Chemotherapy as a Bladder Sparing Strategy for Muscle-Invasive Bladder Cancer

    Gopa Iyer, MD
    Memorial Sloan Kettering Cancer Center

    11:15 AMImmunotherapy: Current Advances through Combination - Identifying the Best Combination

    Joaquim Bellmunt, MD
    Beth Israel Deaconess Medical Center

    11:30 AMPanel Discussion and Q&A 
    11:50 AMLunch 
    12:50 PMSession 4: Translational Science - Moderator's Introduction

    Kent Mouw, MD, PhD
    Dana Farber Cancer Center

    12:55 PMKEYNOTE: Science Behind the Abscopal Effect

    Charles Drake, MD, PhD
    Columbia University Medical Center

    1:25 PMTargeting Hypoxia

    Catharine West, PhD
    University of Manchester, UK

    1:40 PMTranscriptomic Biomarkers in Bladder Preservation Therapy

    David Miyamoto, MD, PhD
    Massachusetts General Hospital

    1:55 PMUrine Biopsy as a Dynamic Marker to Enhance Clinical Staging of Urothelial Cancer

    Phillip Abbosh, MD, PhD
    Fox Chase Cancer Center

    2:10 PMDNA Damage and Mutation Repair

    Kent Mouw, MD, PhD
    Dana Faber Cancer Center

    2:30 PMPanel Discussion and Q&A 
    2:50 PMClosing Discussion, Looking Ahead 
    3:00 PMAdjourn Meeting 
    Johns Hopkins Hospital, Koch Cancer Research Building, Albert H. Owens Auditorium
    1550 Orleans Street
    Baltimore, MD 21287
    United States


    While we do not have a discounted block of rooms reserved at any specific hotels for this meeting, shuttle service will be available between the Hilton Garden Inn Baltimore Inner Harbor and the Koch Cancer Research Building. If you would like to reserve your space on this shuttle, please email Kaili Johnson at to guarantee your space on the bus.

    Hilton Garden Inn Baltimore Inner Harbor
    625 S President St.
    Baltimore, MD 21202


    The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


     The American Urological Association designates this live activity for a maximum of 9.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.


     It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.


    All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.


    All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

    • Peer review for valid, evidence‐based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Conflict of Interest Review Work Group or its subgroup.
    • Limit content to evidence with no recommendations
    • Introduction of a debate format with an unbiased moderator (point‐counterpoint)
    • Inclusion of moderated panel discussion
    • Publication of a parallel or rebuttal article for an article that is felt to be biased
    • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
    • Divestiture of the relationship by faculty


    The audience is advised that this continuing medical education activity may contain reference(s) to off‐label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

    Available Credit

    • 9.50 AMA PRA Category 1 Credit™
    • 9.50 Non-Physician Participation


    Please login or register to take this course.

    Course Registration Fees

    The registration deadline is February 24, 2020.

     AUA MemberNon-Member
    PhD Research Scientist$200$250
    Resident, Fellow, Trainee, or Student$150$175
    Medical Professional Employed by Industry*$450 (Please call AUA Customer Service at 1-800-908-9414 to register by phone.)

    *For exhibit/promotional opportunities, please contact Keith Price at or at 410-689-3749.

    Cancellation Policy

    Cancellation requests must be made in writing prior to February 24, 2020. Requests may be made via email to or fax to 410-689-3912. Please call 1-800-908-9414 or email with any questions related to registration.

    Participant Information & Policies

    Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

    Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.

    Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

    Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

    Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.